Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07755436 |
| Title | Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. |
| Recruitment | Recruiting |
| Gender | female |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | ArriVent BioPharma, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Sarah Cannon Research Institute at Florida Cancer Specialists | RECRUITING | Orlando | Florida | 32827 | United States | Details |
| Dana-Farber Cancer Institute | RECRUITING | Boston | Massachusetts | 02215 | United States | Details |
| Sarah Cannon Research Institute | RECRUITING | Nashville | Tennessee | 37203 | United States | Details |
| MD Anderson Cancer Center | RECRUITING | Houston | Texas | 77030 | United States | Details |
| NEXT Oncology | RECRUITING | Irving | Texas | 75039 | United States | Details |
| NEXT Oncology | RECRUITING | Fairfax | Virginia | 22031 | United States | Details |